We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$870M
AUM Growth
-$103M
Cap. Flow
-$99.3M
Cap. Flow %
-11.41%
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$31.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$18.9M
3
DXCM icon
DexCom
DXCM
+$12.6M
4
COO icon
Cooper Companies
COO
+$10.8M
5
ELV icon
Elevance Health
ELV
+$10.4M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$24.2M
2
MRK icon
Merck
MRK
+$22.8M
3
CI icon
Cigna
CI
+$15.1M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$14.7M
5
BSX icon
Boston Scientific
BSX
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$40.6M 4.66%
77,430
+16,900
+28% +$8.64M
LLY icon
2
Eli Lilly
LLY
$1.02T
$34.5M 3.96%
41,750
-3,700
-8% -$3.08M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$121B
$32.4M 3.72%
66,750
+16,750
+34% +$7.81M
MCK icon
4
McKesson
MCK
$100B
$31.8M 3.65%
47,217
+13,100
+38% +$8.1M
BSX icon
5
Boston Scientific
BSX
$69.5B
$30.3M 3.48%
300,000
-144,000
-32% -$14.5M
GKOS icon
6
Glaukos
GKOS
$9.83B
$26.6M 3.05%
270,000
+233,469
+639% +$31.1M
GILD icon
7
Gilead Sciences
GILD
$162B
$26.2M 3.01%
233,500
-22,000
-9% -$2.27M
PRCT icon
8
Procept Biorobotics
PRCT
$1.06B
$26.1M 3%
448,000
+27,655
+7% +$1.89M
ISRG icon
9
Intuitive Surgical
ISRG
$127B
$25.5M 2.93%
51,500
-12,500
-20% -$6.91M
ALHC icon
10
Alignment Healthcare
ALHC
$3.08B
$24.9M 2.86%
1,337,284
-423,908
-24% -$6.32M
MDT icon
11
Medtronic
MDT
$109B
$22.9M 2.63%
255,000
-14,500
-5% -$1.3M
MOH icon
12
Molina Healthcare
MOH
$10.2B
$22.5M 2.58%
68,200
+34,000
+99% +$10.3M
ELV icon
13
Elevance Health
ELV
$81.5B
$21.3M 2.45%
48,950
+25,800
+111% +$10.4M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$78.5B
$20.1M 2.31%
31,750
-11,707
-27% -$8.05M
COO icon
15
Cooper Companies
COO
$14.1B
$19.9M 2.29%
236,000
+121,000
+105% +$10.8M
BMY icon
16
Bristol-Myers Squibb
BMY
$133B
$19.8M 2.28%
+325,000
New +$18.9M
NTRA icon
17
Natera
NTRA
$38.3B
$19.6M 2.25%
138,500
+15,090
+12% +$2.43M
EXAS
18
DELISTED
Exact Sciences
EXAS
$19M 2.19%
440,000
-31,000
-7% -$1.57M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.6B
$18.7M 2.15%
265,000
+14,377
+6% +$967K
ABBV icon
20
AbbVie
ABBV
$443B
$18.6M 2.13%
88,650
-35,500
-29% -$6.9M
THC icon
21
Tenet Healthcare
THC
$20.5B
$17M 1.96%
126,700
-71,000
-36% -$9.35M
PODD icon
22
Insulet
PODD
$11.5B
$16M 1.84%
61,000
+4,000
+7% +$1.08M
CVS icon
23
CVS Health
CVS
$133B
$16M 1.84%
235,862
-31,638
-12% -$1.89M
JAZZ icon
24
Jazz Pharmaceuticals
JAZZ
$15.9B
$15.4M 1.77%
124,300
-21,200
-15% -$2.77M
INSM icon
25
Insmed
INSM
$21.4B
$14.2M 1.63%
185,500
+124,000
+202% +$9.49M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rhenman & Partners Asset Management held 104 positions worth $870M, down 11% from $973M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $99.3M in Q1 2025, closing 10 positions and reducing 55 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Bristol-Myers Squibb worth $19.8M.

  • Rhenman & Partners Asset Management's largest Q1 2025 buy was Bristol-Myers Squibb: 325,000 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Glaukos in Q1 2025, an estimated $31.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $24.2M.
  • Rhenman & Partners Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $14.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $870M portfolio in Q1 2025.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 10 in Q1 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 11% quarter-over-quarter to $870M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.